Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Other Non Operating Income data on record, last reported at -$29000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 81.05% year-over-year to -$29000.0; the TTM value through Sep 2025 reached $1.5 million, up 520.82%, while the annual FY2024 figure was $416000.0, 144.73% up from the prior year.
  • Other Non Operating Income reached -$29000.0 in Q3 2025 per GLUE's latest filing, down from $1.4 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.4 million in Q2 2025 and bottomed at -$779000.0 in Q4 2023.
  • Average Other Non Operating Income over 3 years is $92727.3, with a median of -$29000.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: crashed 666.67% in 2024, then surged 2722.64% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at -$779000.0 in 2023, then soared by 100.26% to $2000.0 in 2024, then crashed by 1550.0% to -$29000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$29000.0 in Q3 2025, $1.4 million in Q2 2025, and $173000.0 in Q1 2025.